<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Thursday, 3 April 2014</title><meta name="title" content="Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Thursday, 3 April 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="03-04-2014" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - In vitro diagnostic medical devices (A7-0327/2013 - Peter Liese) - Thursday, 3 April 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2014-04-03-ITM-009-11_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2014-04-03-ITM-009-11_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03-ITM-009-10_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-10_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-12_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2014-04-03-ITM-009-12_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-03_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-03_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0267(COD)">2012/0267(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0327/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0327_EN.html" class="ring_ref_link">A7-0327/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">PV 22/10/2013 - 4</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">CRE 22/10/2013 - 4</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-006-03_EN.html" class="ring_ref_link">PV 22/10/2013 - 6.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-006-03_EN.html" class="ring_ref_link">CRE 22/10/2013 - 6.3</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_EN.html?textTabled=A-7-2013-0327" class="ring_ref_link">Explanations of votes</a><br />
                        <a href="/doceo/document/PV-7-2014-04-02-ITM-018-12_EN.html" class="ring_ref_link">PV 02/04/2014 - 18.12</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0427_EN.html" class="ring_ref_link">P7_TA(2013)0427</a><br />
                        <a href="/doceo/document/TA-7-2014-0267_EN.html" class="ring_ref_link">P7_TA(2014)0267</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Thursday, 3 April 2014 - Brussels</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.11. In vitro diagnostic medical devices (<a href="/doceo/document/A-7-2013-0327_EN.html">A7-0327/2013</a> - Peter Liese) </td></tr></table>
<a name="4-223-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Γραπτές αιτιολογήσεις ψήφου</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-781"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118860.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudette Abela Baldacchino (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> In-vitro medical devices (IVDs) are devices intended for diagnostic purposes, i.e. tests which are carried out outside the human body (in vitro). This product group covers a huge variety of tests, ranging from self-tests to measure blood sugar values, to HIV and DNA tests. The quality of such tests is crucial, as proper treatment is not possible without precise diagnosis. In the past there have been cases of low quality in-vitro devices. This poses a serious threat to patient safety.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-804"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Aprovo o presente relatório considerando que a relação entre dispositivos médicos seguros e de elevada qualidade e o objetivo geral de garantir a saúde e a segurança dos utilizadores, pacientes e terceiros, permite sinergias entre o regulamento proposto e a legislação comunitária aplicável em matéria de saúde e segurança no trabalho. O presente regulamento deve, por conseguinte, conter referências explícitas a legislação que estabeleça níveis elevados de segurança para os utilizadores e os pacientes no contexto dos cuidados de saúde e ter em conta as características relativas à conceção e ao desempenho dos dispositivos médicos referidas nas diretivas pertinentes da União em matéria de saúde e segurança no trabalho. Assim, é inteiramente lógico que uma tal disposição seja reconhecida nos requisitos gerais de segurança e desempenho dos dispositivos do Regulamento relativo aos dispositivos médicos. Sou da opinião que as instituições de saúde têm de garantir que os funcionários recebem a formação necessária para o uso correto dos dispositivos médicos, dos instrumentos e das práticas que contribuem para reduzir os ferimentos com seringas, a transmissão de infeções associadas e outros efeitos adversos, de forma a garantir a utilização eficaz e segura das novas tecnologias médicas e das técnicas cirúrgicas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-828"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96814.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Băsescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am susținut acest raport deoarece reglementarea în domeniul dispozitivelor medicale pentru diagnostic în vitro trebuie să fie una clară și unitară. Acest regulament apare și în contextul progreselor științifice și tehnologice în domeniu din ultimii ani, progrese care au generat diferențe substanțiale în ceea ce privește interpretarea și aplicarea normelor. Noul cadru de reglementare, clar și transparent, va soluționa toate aceste neajunsuri și va duce în mod implicit la creșterea nivelului de siguranță a pacienților, precum și a cadrelor medicale. Un alt aspect important este faptul că o astfel de legislație unitară are potențialul de a sprijini și a încuraja inovația, mărind astfel competitivitatea din domeniul industriei dispozitivelor medicale pentru diagnostic in vitro.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-863"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28214.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Bennahmias (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Cette résolution législative reprenant les travaux examinés en octobre 2013 tend à l'harmonisation des dispositifs médicaux de diagnostic in vitro en Europe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-051"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118709.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Fabrizio Bertot (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> In linea con il PPE ho votato a favore della relazione sui dispositivi medico-diagnostici in vitro (IVD) quali strumento imprescindibile per analisi di laboratorio e per quelle decentrate in caso di ricovero, includendo un ampio ventaglio di esami autodiagnostici come la misurazione della glicemia, i test HIV e i test del DNA. Risulta necessario migliorare la normativa sui dispositivi medici IVD poiché vi è la priorità assoluta di identificare nel più breve tempo possibile il trattamento migliore per curare un paziente e questo implica inesorabilmente l'uso di dispositivi di alta qualità. Pertanto, ciò di cui abbiamo bisogno è regolamentare l'immissione sul mercato di dispositivi con marcatura CE che non rispettano gli standard prefissati dall'UE. Essa, infatti, deve garantire la massima sicurezza possibile sia per tutelare l'utilizzatore, sia per regolamentare il mercato in sé. A tal proposito sarà necessario potenziare sempre più la vigilanza sul mercato, introducendo ispezioni obbligatorie alle imprese senza preavviso. Per poter salvaguardare nel modo migliore la salute del consumatore è necessario inoltre intervenire sui seguenti punti: sistema degli organismi notificati, studi della prestazione clinica, classificazione, esami interni e i test diagnostici di accompagnamento, test autodiagnostici e analisi decentrate, campo di applicazione e il periodo di transizione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-869"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Pur condividendo alcune parti della relazione Liese sui dispositivi medico-diagnostici e la necessità di un miglioramento del regolamento in essere, ritengo che taluni aspetti sviluppati siano controversi e porterebbero ad un aggravio delle spese senza un reale aumento della sicurezza. Per questi motivi, mi sono espressa con voto di astensione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-872"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29074.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vito Bonsignore (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Allo stato delle nostre conoscenze tecniche e della qualità del materiale disponibile sul mercato globale, il problema dei falsi negativi resta, purtroppo, un'emergenza a due cifre. A tutela dei diritti fondamentali stabiliti nella Carta dell'UE, il legislatore deve perciò dimostrare di aver posto in essere ogni ragionevole precauzione e ogni misura possibile di minimizzazione del rischio iatrogeno. In questo senso, le soluzioni offerte dalla relazione mi paiono equilibrate. Tra queste, richiamo il regime molto più stretto per IVD di classe D, fondato su una supervisione esterna, la pubblicità di tutte le fasi di test in R&amp;S, la estesa facoltà di accesso da parte dei privati, il ruolo del comitato etico in fase di preventiva autorizzazione e la costituzione di un <span class="italic">advisory board</span> europeo permanente per la verifica periodica della legge. Le consultazioni con gli <span class="italic">stakeholder</span> hanno dimostrato un'ampia disponibilità, anche da parte delle imprese, ad accettare misure che in altri contesti potrebbero apparire onerose o ridondanti, ma che in questo caso garantiscono una clima di <span class="italic">social acceptance</span> e prevengono fenomeni di caccia alle streghe. Un singolo incidente, in questo settore, minaccia l'intera filiera e innescherebbe fenomeni di panico dagli effetti imprevedibili. Voto senz'altro a favore della relazione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-873"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Osnovni cilj regulative o <span class="italic">in vitro</span> medicinskim proizvodima je usklađivanje zakona i pravila s napretkom i novim spoznajama u medicini. Od kada je na snazi prijašnja direktiva, napravljeni su veliki koraci naprijed u upotrebi implantata i raznih medicinskih uređaja. No napravljeni su i koraci unatrag u zaštiti pacijenata, što su zorno pokazali skandali s otrovnim silikonskim umetcima i umjetnim kukovima. Nužna su nova pravila koja će pronaći ravnotežu između potrebe za bržim puštanjem na tržište novih, potencijalno spasonosnih uređaja i pružanjem maksimalne zaštite korisnika. </p>
<p class="contents">Zato žalim što se Europsko vijeće nije moglo usuglasiti oko stajališta o ovoj regulativi. Samo se nadam da radi njihove neodlučnosti neće biti novih stradanja pacijenata. Imali smo priliku vidjeti kada se dogode medicinski skandali, javnost upire prstom upravo u smjeru institucija Europske unije.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-015"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96603.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nessa Childers (NI), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> From hip implants to pacemakers and breast implants, consumers use medical devices on a day-to-day basis and these products most often contribute significantly to people’s health and well-being. Medical devices make hearts beat and allow people to walk and, if not of a high quality, they could jeopardise consumer’s lives. Therefore, it is only right that there is a regulatory framework in place that guarantees that these products are safe and effective. This is about balancing patient safety, which should be the first priority, with swift access to the EU market and innovation by medical device companies. Patient safety should always be a priority and that is why I voted in favour of this opportunity to enhance patient care and safety and ensure the highest standards of medical devices.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-445"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113597.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Minodora Cliveti (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Dispozitivele medicale DIV sunt dispozitive medicale pentru diagnosticul în afara corpului uman (in vitro), care poate fi realizat în laborator sau în proximitatea pacientului, de exemplu lângă pat. Această noțiune cuprinde o varietate enormă de teste, cum ar fi autotestarea pentru măsurarea glicemiei, testele HIV și testele ADN. Organismele notificate trebuie îmbunătățite substanțial și trebuie consolidată monitorizarea organismelor notificate de către statele membre. Este foarte importantă consolidarea sistemul de vigilență și de supraveghere a pieței. Efectuarea de inspecții neanunțate la întreprinderi va fi obligatorie. În plus, Comisia propune introducerea unei rețele de laboratoare europene de referință, care au un rol important în controlul dispozitivelor medicale cu risc ridicat și care vor ameliora considerabil siguranța pacienților. </p>
<p class="contents">Totodată, sunt introduse trei îmbunătățiri majore cu privire la trialurile clinice: înainte de a fi inițiat, studiul referitor la performanța clinică ar trebui să fie evaluat pozitiv de un comitet de etică independent; protecția minorilor și a altor persoane care nu sunt în măsură să își dea consimțământul în cunoștință de cauză ar trebui reglementată la fel ca în Directiva din 2001 privind trialurile clinice; termenele ar trebui extinse în mod moderat, pentru a oferi comitetului de etică și autorităților timpul necesar pentru a evalua propunerea.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-458"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lara Comi (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> Accolgo con favore la proposta della Commissione di istituire un regolamento ad hoc per i dispositivi diagnostici in vitro (IVD) e voto a favore di questa relazione che apporta ulteriori migliorie al fine di garantire una sicurezza sempre maggiore in ambito sanitario. I dispositivi (IVD) danno un grande contributo alla medicina e alla tutela della salute. Basti pensare che vengono utilizzati per diagnosticare il virus dell'HIV e l'epatite C e per effettuare test del DNA o test nutigenetici (inizialmente non inclusi). L'introduzione o l'utilizzo di dispositivi scadenti (com'è già accaduto più volte in passato) può comportare molti rischi per la salute pubblica. Quindi bisogna garantire con questo regolamento che tutti i dispositivi IVD utilizzati all'interno dell'Unione siano controllati e certificati secondo alti standard di sicurezza. Una nuova garanzia qui proposta è l'obbligo di imporre la stipulazione di un'assicurazione da parte dei fabbricanti di dispositivi a tutela dei pazienti per i quali deve sempre essere garantita una giusta compensazione in caso di errore. Si ritiene che cinque anni per attuare la direttiva, come proposto dalla Commissione, siano troppi, specialmente per alcune materie dove la regolamentazione assume un carattere più urgente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-508"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Ce texte vise à renforcer la législation en vigueur relative aux dispositifs médicaux de diagnostic in vitro, utilisés pour le dépistage et la prévention des maladies, le diagnostic, le suivi des traitements prescrits et l’évaluation des interventions médicales. Ces dispositifs recoupent notamment des autodiagnostics pour la mesure du taux de glycémie, les tests HIV et les tests ADN. </p>
<p class="contents">Étant donné la sensibilité de leur usage, il est de notre devoir en tant que député européen de garantir une sécurité maximale concernant ces dispositifs pour une meilleure protection des citoyens sur le marché intérieur. Il est vital de s'assurer de leur fiabilité et de leur qualité. </p>
<p class="contents">Toutefois, je reconnais que cette modification de la législation doit se faire de manière proportionnée afin de ne pas imposer de charges excessives aux PME qui composent en grande partie ce secteur.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-660"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23868.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Flašíková Beňová (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. -</span> Zdravotnícke pomôcky in vitro sú doležité na použitie pri diagnostike mimo ľudského tela. Bez expertnej diagnostiky nie je možné zaručiť prevenciu ochorení ani riadne ošetrenie. Smernica v jej súčasnej podobe nezaručuje prílev nekvalitných diagnostických výrobkov in vitro na trh. To môže spôsobiť chybné výsledky pri testoch a tým pádom ohroziť verejné zdravie a životy občanov. Je veľmi dôležité, aby Európska únia zabezpečila najvyššiu možnú bezpečnosť svojim občanom, pretože diagnostické zdravotnícke pomôcky in vitro sú výrobky, ktoré sa voľne vyskytujú na voľnom trhu a neexistujú pre ne žiadne národné hranice. Európska komisia navrhuje podstatné zlepšenia v oblasti posilnenia a dohľadu členských štátov nad notifikovanými orgánmi, pretože je veľmi dôležité, aby sa posilnil dohľad na trhom. Medzi opatrenia, ktoré Európska komisia plánuje zaviesť, patria napríklad neohlásené inšpekcie v podnikoch alebo vytvorenie siete európskych referenčných laboratórií, ktoré by zohrávali dôležitú úlohu pri kontrole rizikových zdravotníckych pomôcok. Európska únia by sa nemala snažiť obmedzovať pacientov a ich prístup k testom DNA, ale mala by poskytovať a zabezpečiť profesionálne a odborné poradenstvo s cieľom informovať o následkoch pred uskutočnením testu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-767"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118999.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Franco Frigo (S&amp;D), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La Commissione ha proposto miglioramenti importanti al fine di colmare le carenze attuali del sistema per i dispositivi medici IVD, simili a quelli di altri dispositivi medici. Gli organismi notificati saranno migliorati in maniera sostanziale e la vigilanza degli Stati membri sugli organismi notificati sarà rafforzata. Ritengo sia molto importante ridefinire la classificazione e i campi di applicazione, potenziare il sistema della vigilanza e della sorveglianza del mercato e rendere obbligatorie le ispezioni senza preavviso presso le imprese. Inoltre, la Commissione propone di introdurre una rete di laboratori di riferimento europei, che rivestano un ruolo di rilievo nel controllo dei dispositivi medici ad alto rischio. Accolgo favorevolmente tali proposte che, a mio parere, miglioreranno considerevolmente la sicurezza dei pazienti.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-773"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ildikó Gáll-Pelcz (PPE), </span></span>  <span class="italic">írásban</span><span class="bold">. -</span> Pozitív szavazatommal támogattam a jelentést, mert az előadóval egyetértve meggyőződésem, hogy e rendelet célja az orvostechnikai eszközök magas színvonalának és nagyfokú biztonságosságának, valamint ezzel együtt a betegek, a felhasználók és más személyek egészsége és biztonsága magas szintű védelmének garantálása. Üdvözlendőnek tartom a jelentésben megfogalmazott prioritásokat, melyek mindenekelőtt a biztonságosságára, minőségére és hatékonyságára vonatkozó normák szabályozása. Elsősorban szeretném kiemelni az egészség és biztonság fontosságát a jelentésben, mely többek között ily módon fogalmazódik meg: „az eszközöket és a gyártási folyamatokat úgy kell megtervezni, hogy kiküszöbölhető vagy a lehető legkisebbre csökkenthető legyen a betegeket, a professzionális vagy laikus felhasználókat és adott esetben egyéb személyeket érő fertőzés kockázata. Az eszközök sem a betegeknek, sem a felhasználóknak, sem másoknak nem okozhatnak sérüléseket”. Kiemelten fontosnak tartom felhívni a figyelmet az egészségügyi dolgozók képzésének fontosságára is, tehát az egészségügyi intézményeknek az új orvosi technológiák és sebészeti technikák biztonságos alkalmazása érdekében gondoskodniuk kell arról, hogy alkalmazottaik megkapják az orvostechnikai eszközök, felszerelések és eljárások megfelelő alkalmazásáról szóló képzést. Támogatom azt, hogy az egészségügyi ellátással összefüggő fertőzések és más kedvezőtlen hatások visszaszorítása érdekében az egészségügyi személyzet minden tagja számára megfelelő védelmet kell biztosítani oltások, rendszeres diagnosztikai vizsgálat, egyéni védőfelszerelés alkalmazása révén.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-776"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai également voté en faveur de ce règlement qui vise à renforcer la sécurité des dispositifs médicaux de diagnostic in vitro destinés à un usage diagnostic en dehors du corps humain, c'est-à-dire dans un laboratoire ou à proximité du patient, par exemple à son chevet. Ils couvrent une très grande variété de tests, tels que des autodiagnostics pour la mesure du taux de glycémie, les tests HIV et les tests ADN. Les droits et les responsabilités des fabricants, des importateurs et des distributeurs ont été clarifiés, y compris en ce qui concerne les services diagnostics et la vente en ligne. Là encore, il conviendra de s'assurer que l'examen de la seconde lecture préserve ces impératifs liés à la sécurité pour les patients.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-778"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Juozas Imbrasas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. -</span> Pritariau šiems pasiūlymams, kurie padės iš esmės pagerinti pacientų saugą. IVD medicinos prietaisai nėra mažasis elementas, o vieni iš svarbiausių medicinos prietaisų ir gali būti visų terapijų, įskaitant farmacijos produktus ir chirurgiją, pagrindas. Jei nebus tinkamos diagnostikos, nebus tinkamo ligų gydymo ar prevencijos. Deja, pagal galiojančią direktyvą neužtikrinama, kad į rinką nebūtų tiekiami žemos kokybės IVD medicinos prietaisai. Todėl šiuo pasiūlymu yra siekiama ištaisyti šią situaciją.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-780"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur du rapport de mon collègue Peter Liese sur les dispositifs médicaux de diagnostic in vitro. Ce texte avait fait l'objet d'un vote en octobre 2013, mais le vote final avait été repoussé afin que le rapporteur puisse négocier avec le Conseil et obtenir un accord qui aurait ensuite été validé par le Parlement. Le Conseil n'ayant pas pu trouver d'accord entre ses membres sur sa propre version du texte, les négociations n'ont pas pu commencer. Le Parlement devait donc se prononcer sur sa propre version du texte, afin que celle-ci puisse être transmise à la prochaine législature et faire l'objet d'un accord en seconde lecture. Le rapport a été adopté par 492 voix pour, 21 voix contre et 117 abstentions. Je me félicite de ce résultat.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-800"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> L'obiettivo della presente relazione è quello di apportare miglioramenti importanti per risolvere le carenze del sistema per i dispositivi medico-diagnostici in vitro. Si tratta di dispositivi medici destinati a un uso diagnostico esterno al corpo umano, sia in laboratorio che per analisi decentrate, e comprendono una vasta gamma di esami, come quelli autodiagnostici per la misurazione della glicemia, i test HIV e i test del DNA. I dispositivi medici IVD sono prodotti che possono circolare liberamente nel mercato unico, ed è per questo che l'Unione europea deve garantire la massima sicurezza possibile, potenziare il sistema di vigilanza e sorveglianza del mercato per tutelare i cittadini ed evitare che siano immessi nel mercato dispositivi di bassa qualità, in grado di mettere a rischio la salute dei cittadini europei.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-821"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23704.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jiří Maštálka (GUE/NGL), </span></span>  <span class="italic">písemně</span><span class="bold">. -</span> Cíle směřující ke zvýšení bezpečnosti pacientů, zdravotnického personálu a jejich zavádění do praxe jsou pro mě jako lékaře vždy citlivou otázkou. Jak v tomto návrhu vztaženému ke zdravotnickým prostředkům in vitro, tak i v souvisejícím návrhu o zdravotnických prostředcích se podle mne jedná o takové změny, které jsou postaveny na základě reflektování současného vývoje, na současných možnostech a moderních trendech. Systém sdílení nezbytných dat v rámci informační databáze či propojení informačních systémů vedoucí k možnosti efektivní sledovatelnosti, dohledání zdravotnického prostředku od jeho vzniku až k[nbsp ]pacientům nebo zdravotnickému personálu je jednou ze součástí, které můžou významně zvýšit zmiňovanou úroveň bezpečnosti i přispět k nutné úrovni informovanosti. Úprava a harmonizace pravidel se zachováním deklarovaného účelu je v návrhu citlivě zapracována a domnívám se, že předložený text má ve své oblasti výraznou přidanou hodnotu. Z těchto důvodů jsem návrh podpořil.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-848"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/39916.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zofija Mazej Kukovič (PPE), </span></span>  <span class="italic">pisno</span><span class="bold">. -</span> Toplo pozdravljam odločitev Evropskega parlamenta, da sprejme uredbo o <span class="italic">in vitro</span> diagnostičnih medicinskih pripomočkih. Tako, kot je potrebna večja varnost za paciente, ki uporabljajo medicinske pripomočke, potrebujemo tudi dodatna zagotovila, da so orodja, s katerimi odkrivamo bolezni in zdravstvene težave, primerne kvalitete. Kvaliteto zdravstvenih storitev ter zaupanje v postavljene diagnoze bo zagotovil okrepljen nadzor nad diagnostičnimi pripomočki, proizvajalci bodo morali zagotoviti sledljivost in poročati odgovornim telesom, javnost in zdravstveni delavci pa bodo imeli boljši dostop do informacij. Dosegli smo tudi višjo raven zaščite pravic pacientov, predvsem kar zadeva pravico o odločanju o izvajanju testiranja. Na primer, tisti, ki bodo želeli opraviti genetske teste, bodo morali biti poučeni o vseh vidikih njihove odločitve ter dati končno soglasje za opravljanje testa. V skladu z nacionalno zakonodajo bo potrebno pridobiti tudi dovoljenje za opravljanje diagnostičnih testiranj pri mladoletnikih in onesposobljenih osebah. Uredba je z upoštevanjem vloge, ki jo imajo mala in srednja podjetja na področju <span class="italic">in vitro</span> diagnostičnih pripomočkov, izboljšala njihovo konkurenčnost. Mnoge takšne naprave v Evropski uniji izdelujejo prav takšna podjetja in uredba bo znižala bremena, s katerimi se soočajo. Primer tega je recimo sporočanje določenih informacij v elektronski obliki. Tako bomo poleg zdravja zagotovili tudi dodatna delovna mesta.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-861"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96817.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Erminia Mazzoni (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> L'attuale quadro normativo comunitario non prevede disposizioni in grado di impedire l'immissione nel mercato di dispositivi medici IVD (diagnostici in vitro) di bassa qualità. Questa lacuna normativa ha rischiato per troppo tempo di avere conseguenze drammatiche. Diagnosi e prevenzione sono probabilmente le fasi più delicate e critiche che la scienza deve affrontare. Alla luce di tutto ciò, ho sostenuto con convinzione l'introduzione di standard europei di riferimento obbligatori al fine di garantire una stretta e rigida vigilanza nel settore, trasparenza e informazione ai pazienti e protezione della salute pubblica.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-864"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Les dispositifs médicaux in vitro sont des dispositifs médicaux destinés à un usage diagnostique en dehors du corps humain, c'est-à-dire dans un laboratoire ou à proximité du patient. Ils couvrent une très grande variété de tests, tels que des autodiagnostics pour la mesure du taux de glycémie, les test HIV et les tests ADN. </p>
<p class="contents">Le rapport propose diverses améliorations. Un nouveau système de classification selon le risque est proposé. Le système de surveillance du marché et de vigilance sera renforcé. Les inspections inopinées des entreprises seront obligatoires. Le rapport permet également l'instauration d'un réseau de laboratoires européens de référence. </p>
<p class="contents">Le rapport ignore la question cruciale des conditions sociales et écologiques de production de ces dispositifs médicaux. En l'absence d'une telle harmonisation sociale, la libre circulation des dispositifs médicaux augmente les risques de délocalisation des fabricants. La France y est lourdement exposée puisqu'elle importe déjà 55[nbsp ]% des dispositifs médicaux consommés. Pourtant sa capacité de production continue de décliner, comme l'a montré la fermeture de l'usine Sodimedical.&#x2028;</p>
<p class="contents">Je vote pour, pour appuyer les avancées normatives dans l'encadrement des produits. Mais je déplore une nouvelle étape de la libéralisation du marché des biens au détriment des travailleurs et de l'objectif de relocalisation des productions au plus près de leur consommation.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-052"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Este relatório visa aprovar novas regras sobre os dispositivos de diagnóstico in vitro usados em testes de gravidez, ADN ou HIV. Os dispositivos médicos de diagnóstico in vitro abrangem uma vasta gama de produtos, como testes de gravidez, testes de despistagem de HIV, testes de ADN, etc.. Existem milhares de diferentes dispositivos com diferentes categorias de risco. As regras hoje aprovadas têm em vista garantir a segurança dos pacientes. Foram introduzidas novas regras sobre o consentimento dos pacientes sobre a utilização de um dispositivo para fins de testes genéticos, tendo sido aconselhado a criação de um comité de ética. As regras hoje aprovadas têm em vista garantir a segurança dos pacientes. Daí o meu voto favorável.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-866"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I have voted in favour of this proposal for a regulation of the European Parliament and of the Council on in-vitro diagnostic medical devices. I support this report because in-vitro medical devices are useful tools for tests such as self-tests for blood sugar measuring, HIV tests, and DNA tests. This regulation will help ensure only high quality equipment is available on the market to reduce risks of life-threatening false negative results in order to ensure the safety of European citizens.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-087"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. -</span> He votado a favor del presente informe debido a que supone una mejora de la normativa sobre productos sanitarios para el diagnóstico <span class="italic">in vitro</span> que permitirá terminar con la incoherencia entre las diferentes regulaciones nacionales en la Unión Europea. El informe desarrolla una clasificación de este tipo de productos en función de los riesgos que acarrean para el usuario y para la salud pública, permitiendo un tratamiento adecuado para cada tipo de producto. Este informe incluye una mejora de la transparencia relativa a los potenciales usos, la protección de los menores y de las personas con discapacidad, incluye una exención de la normativa en caso de productos de uso en el domicilio, etc. Todos estos principios constituyen un informe que mejora la protección de los usuarios de este tipo de productos y es por esto por lo que he decidido votar a favor del mismo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-870"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE), </span></span>  <span class="italic">písomne</span><span class="bold">. -</span> Používanie zdravotníckych pomôcok in[nbsp ]vitro má mnohé špecifiká, klinické a[nbsp ]zdravotné dosahy, keďže in vitro pomôcky sa používajú napríklad pri zisťovaní tehotenstva, testovaní DNA alebo zisťovaní HIV. Posilnenie záruk bezpečnosti sa týka aj záruk proti zlyhaniu takýchto pomôcok, ktoré môže mať v[nbsp ]konkrétnych prípadoch ďalekosiahle negatívne dôsledky. Napríklad v[nbsp ]prípade nespoľahlivého zisťovania HIV hrozí nebezpečenstvo kontaminácie ďalších pacientov, ak by malo dôjsť k[nbsp ]transfúzii krvi alebo iným kontaktom. V[nbsp ]oblasti genetického testovania podporujem posilnenie etických princípov pri používaní takýchto pomôcok a[nbsp ]predovšetkým zavedenie povinného informovaného súhlasu pacienta pred takýmto testovaním. V[nbsp ]záujme podpory zvyšovania bezpečnosti používania zdravotníckych pomôcok in vitro v[nbsp ]Európskej únie som hlasoval za prijatie predkladaného návrhu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-871"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted in favour of this report, which calls for improved patient safety and better protection of patients from defective medical devices through a more effective and efficient system for granting market access. Patient safety is essential and therefore it is important to increase the quality of in-vitro devices.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-657"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96653.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Katarína Neveďalová (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. -</span> Zdravie a[nbsp ]bezpečnosť diagnostických zariadení či pomôcok patrí medzi priority EÚ, spadajú sem aj diagnostické pomôcky in vitro. Tieto zdravotnícke pomôcky sú určené na použitie pri diagnostike mimo tela, čiže sa môže uskutočňovať v[nbsp ]laboratóriu alebo v[nbsp ]blízkosti pacienta, napríklad pri posteli. Spadá sem široká škála testov, ako je meranie cukru v[nbsp ]krvi, testy na HIV či testy DNA. Diagnostické zdravotnícke pomôcky in vitro sú výrobky, ktoré sa voľne vyskytujú na[nbsp ]spoločnom trhu. Medzi zdravotnícke pomôcky je zahrnutých viac ako milión rôznych výrobkov. V[nbsp ]Európe v[nbsp ]súčasnosti pôsobí viac ako 25[nbsp ]tisíc firiem, ktoré sa venujú medicínskym technológiám. Len za rok 2012 EÚ evidovala 10[nbsp ]tisíc žiadostí o[nbsp ]patent. Existuje mnoho otázok, v[nbsp ]ktorých Európska komisia navrhuje regulovať diagnostické zdravotnícke pomôcky in vitro rovnakým spôsobom ako ostatné zdravotnícke pomôcky. Na európskom trhu neexistujú pre tieto výrobky žiadne národné hranice. Preto je Európska únia povinná zaistiť najväčšiu možnú bezpečnosť.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-550"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/30482.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Younous Omarjee (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Les dispositifs médicaux de diagnostic in vitro (DIV) sont des appareils utilisés à l'extérieur du corps humain, dans un laboratoire ou à proximité du patient. Ils peuvent servir à réaliser une multitude de tests, tels que les tests HIV et tests ADN par exemple. </p>
<p class="contents">Ce rapport propose d'améliorer la réglementation concernant la commercialisation de ces appareils car les taux d'erreur peuvent fortement varier d'un dispositif à un autre, ce qui peut entraîner de mauvais diagnostics et donc de mauvais traitements. Le rapport apporte également une dimension éthique essentielle aux essais cliniques. J'ai donc apporté mon soutien à ce rapport.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-443"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/26829.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Siiri Oviir (ALDE), </span></span>  <span class="italic">kirjalikult</span><span class="bold">. -</span> Toetasin seda määrust, kuna praegune meditsiiniseadmete direktiiv ei taga IVD seadmete ehk väljaspool inimkeha diagnostiliseks kasutamiseks mõeldud meditsiiniseadmete kõrgemat kvaliteeti, et parandada haiguste ennetamist ja ravi. </p>
<p class="contents">Euroopa turul saada olevad ebakvaliteetsed testid on juba põhjustanud väga suurt kahju, kuna on andnud kasutajatele valesid negatiivseid tulemusi, mis on teatavate juhtumite korral soodustanud HIVi ja C-hepatiidi levikut. Madala kvaliteediga testide leviku tõkestamiseks tuleb tugevdada järelevalve- ja turujärelvalve süsteemi ning etteteatamata kontrollkäigud vastavatesse ettevõtetesse peavad mõistagi muutuma kohustuslikuks. </p>
<p class="contents">Selleks et kahju vähendada ja ennetada, peame tegutsema kiirelt. Euroopa Komisjoni esildatud õigusakti viieaastane üleminekuperiood on minu arvates liiga pikk. Mõned määruse osad tuleks kasutusele võtta palju kiiremini, nt need osad, mis puudutavad komisjoni ja liikmesriike.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-016"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97050.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antigoni Papadopoulou (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> IVD medical devices are used for diagnostic use outside the human body. They may be used in a laboratory or in the presence of the patient. Examples include blood sugar measuring tests and HIV tests. The current directive does not ensure that low quality IVD medical devices are not placed on the market, as they can circulate freely in the common market. Therefore the European Union is obliged to ensure the highest possible safety. Notified bodies need to be improved so as to enhance public safety, supervision and control over the entire certification system. Furthermore, it is important that the system of market surveillance and vigilance is strengthened and that unannounced inspections of the companies are compulsory. Moreover, informed consent must be included as it is a crucial element of the Charter of Fundamental Rights.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-230"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Pargneaux (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> J'ai voté en faveur de ce règlement qui vise à mettre en place un cadre réglementaire solide, transparent et durable qui soit propice à l'innovation et à la compétitivité de l'industrie des dispositifs médicaux in vitro et qui permette un accès au marché rapide et financièrement avantageux pour les dispositifs innovants, au profit des patients et des professionnels de la santé.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-391"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36392.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Aldo Patriciello (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> I dispositivi medici IVD sono dispositivi a uso diagnostico esterno al corpo (in vitro) e comprendono una vasta gamma di esami come ad esempio la misurazione della glicemia, i test HIV e i test del DNA. Con l'utilizzo di questi dispositivi i test davano risultati falsi negativi, ossia assenza del virus anche se in realtà era presente. Questo prodotto è stato per anni a disposizione dei pazienti dell'UE. Tali prodotti sono immessi nel mercato europeo è l'Unione europea deve garantire la massima sicurezza possibile, tramite miglioramenti sulla vigilanza e sorveglianza del mercato. Considerando che la proposta si concentra sulla qualità del prodotto, ho espresso il mio voto favorevole alla proposta.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-431"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112744.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tonino Picula (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Brojna znanstvena otkrića kroz stoljeća te ubrzani razvoj znanosti i tehnološki napredak omogućili su nevjerojatan razvoj medicine i razumijevanja ljudskog tijela putem mehanizama laboratorijske dijagnostike. Moderne medicinske metode oslanjaju se velikim dijelom na mogućnost pravilne i pravovremene dijagnoze i stoga su dijagnostički proizvodi, a pogotovo njihova sigurnost, ne samo za pacijente, već i za profesionalno osoblje koje njima barata, iznimno važni za napredak zdravstvenog sustava Unije. </p>
<p class="contents">Pozdravljam ciljeve koji se protežu kroz izvješće, a to su zdravlje i sigurnost. Podržavam i prijedlog Komisije da u opseg regulacije unese i prediktivne genetičke testove koji pružaju informaciju o genetskim predispozicijama za određenu bolest budući da je u tim slučajevima moguće poduzeti preventivne mjere i prije nego se pokažu prvi simptomi bolesti, što potencijalno može spasiti mnoge živote građana diljem Europske unije.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-552"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> I dispositivi medici IVD sono prodotti che possono circolare liberamente nel mercato unico, motivo per cui l'UE ha il compito di garantire la massima sicurezza possibile per i consumatori. Noto con piacere il fatto che la proposta ha voluto tenere conto delle PMI, tramite una serie di emendamenti che tengono conto della capacità e dei limiti di queste imprese. Appoggio pienamente il proposito di tenere in conto i diritti delle persone con disabilità, in particolare con riferimento alla convenzione ONU ratificata dall'Unione. Infine, in merito agli atti delegati, ritengo che la Commissione non debba poter godere della possibilità di modificare tramite questo strumento giuridico settori come i requisiti generali di sicurezza e prestazione, la dichiarazione tecnica di conformità e l'integrazione e la modifica delle procedure di valutazione di conformità.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-592"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119435.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Davor Ivo Stier (PPE), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Bez odgovarajuće medicinske dijagnostičke opreme nema odgovarajućeg liječenja ili prevencije bolesti. Cilj je zamjena postojeće direktive novom regulacijom čija bi zadaća bila povećati zaštitu javnog zdravstva i sigurnosti, povećanje transparentnosti informacija prema pacijentima, otklanjanje prepreka na unutarnjem tržištu, kao i jačanje pravila sljedivosti. To bi se postiglo proširenjem te usklađivanjem zakonodavstva. IVD medicinski uređaji su medicinski proizvodi namijenjeni <span class="italic">in vitro</span> uporabi, a svoju korisnost osim u labarotoriju našli su i kod pacijenata u kućnoj uporabi, primjerice kraj kreveta. Pokrivaju široki raspon različitih testova, kao što su self test za mjerenje šećera u krvi, HIV tetovi i DNK testovi. Komisiji je vrlo važna kvaliteta proizvoda dok stručnjaci i mnoge međunarodne organizacije, poput Vijeća Europe, OECD-a i Europskog društva za humanu genetiku zauzimaju stav kojim ističu da su u mnogim slučajevima od kvalitete proizvoda važniji slučajevi u kojima se primjenjuje proizvod. <span class="italic">In vitro</span> dijagnostički medicinski proizvodi imaju posebne značajke u pogledu klasifikacije rizika, postupaka ocjenjivanja sukladnosti i kliničkih dokaza zbog kojih je potrebno donijeti poseban zakon, odvojen od zakona o drugim medicinskim proizvodima, a horizontalni aspekti koji su zajednički obama sektorima trebali bi se uskladiti, ne dovodeći u pitanje potrebu za inovacijama u Uniji.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-632"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> This proposal for a new regulation is replacing the existing Directive on in-vitro diagnostic medical devices (IVD) with the aim of addressing inconsistencies in Member Statesʼ interpretation of current rules as well as increasing the protection of public health and safety. However, a compromise proposed whereby genetic testing was to be excluded from the regulation was not agreed to, therefore I could not vote in favour of the final report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-692"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> Il y a un consensus sur le fait que l'Union européenne ne devrait pas s'efforcer de limiter l'accès des patients aux tests ADN mais qu'un conseil génétique approprié devrait être systématiquement proposé pour les informer des conséquences avant l'exécution du test. Pour respecter le principe de subsidiarité, il devrait appartenir aux États membres de réglementer les modalités et les États membres devraient avoir la possibilité d'aller plus loin que ce que requiert le règlement. On pourrait même dire qu'il est obligatoire d'inclure le consentement éclairé dans la proposition parce qu'il s'agit d'un élément crucial de la Charte des droits fondamentaux (article 3) et que la Charte des droits fondamentaux est juridiquement contraignante pour l'Union européenne dans les domaines où elle intervient.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-722"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am votat pentru raportul referitor la propunerea de regulament privind dispozitivele medicale pentru diagnostic in vitro. Dispozitivele medicale DIV sunt dispozitive medicale pentru diagnosticul în afara corpului uman (in vitro), care poate fi realizat în laborator sau în proximitatea pacientului, de exemplu lângă pat. Această noțiune cuprinde o varietate enormă de teste, cum ar fi autotestarea pentru măsurarea glicemiei, testele HIV și testele ADN. Dispozitivele medicale DIV sunt produse care pot circula liber pe piața comună și, de aceea, Uniunea Europeană este obligată să asigure cel mai înalt nivel de siguranță posibil. </p>
<p class="contents">Propunerea Comisiei include îmbunătățiri majore pentru remedierea lacunelor actuale ale sistemului pentru dispozitivele medicale DIV, similar celor pentru alte dispozitive medicale. Organismele notificate vor fi îmbunătățite substanțial și va fi consolidată monitorizarea organismelor notificate de către statele membre. Este foarte important că va fi consolidat sistemul de vigilență și de supraveghere a pieței. În plus, Comisia propune introducerea unei rețele de laboratoare europene de referință, care au un rol important în controlul dispozitivelor medicale cu risc ridicat. </p>
<p class="contents">Parlamentul a amendat propunerea Comisiei pentru a ține seama de capacitatea și nevoile IMM-urilor, precum posibilitatea de a furniza informații și pe cale electronică, iar informațiile care însoțesc produsul trebuie furnizate într-o limbă oficială a Uniunii.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="4-223-753"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119431.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ruža Tomašić (ECR), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Podržala sam ovaj prijedlog jer osim što je bilo prijeko potrebno izmijeniti Uredbu o "in vitro" dijagnostičkim medicinskim proizvodima koja nije pružila dovoljne garancije u zaštiti javnog zdravstva i sigurnosti, ona jasnije definira ulogu prijavljenih tijela, uvodi za proizvođače obvezu sklapanja police osiguranja od odgovornosti koja bi pokrivala štetu nastalu za pacijente ili korisnike koju se može izravno povezati s proizvodnim nedostatkom medicinskog proizvoda te omogućava javnosti ali i zdravstvenom osoblju lakši pristup informacijama. S druge strane, predloženi sustav uvodi određene garancije glede pristanka sudionika za ispitivanje: pristanak mora biti informiran i slobodan, u pismenom obliku te može biti povučen u svakom trenutku pismenim ili usmenim putem.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
